Moore Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Moore Capital Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-403,300	Closed	-$9.28M	–	778
2025 Q4	$9.28M	Buy	+403,300	New	+$13.3M	0.13%	169
2025 Q1	–	Sell	-50,000	Closed	-$2.1M	–	599
2024 Q4	$2.1M	Sell	50,000 -50,000	-50%	-$2.48M	0.02%	323
2024 Q3	$5.55M	Hold	100,000	–	–	0.1%	209
2024 Q2	$4.11M	Buy	100,000 +25,000	+33%	+$1.07M	0.07%	225
2024 Q1	$3.5M	Buy	+75,000	New	+$3.54M	0.06%	231

Other funds holding RARE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Moore Capital Management's RARE Position: Q2 2026 in Review

Moore Capital Management reduced its Ultragenyx Pharmaceutical (RARE) stake by 19% in Q2 2026, selling an estimated $723K and leaving 128,035 shares worth $4.28M. The position accounts for 0.06% of the portfolio, ranked #258.

Moore Capital Management first reported a position in RARE in Q1 2015 and has held it in 16 quarters since. The position peaked at $13.6M in Q3 2024. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

Moore Capital Management held 128,035 shares of Ultragenyx Pharmaceutical worth $4.28M as of Q2 2026.
Moore Capital Management sold 29,097 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $723K.
Ultragenyx Pharmaceutical made up 0.06% of Moore Capital Management's portfolio in Q2 2026, its #258 holding.
Moore Capital Management first reported a position in Ultragenyx Pharmaceutical in Q1 2015 and has held it in 16 quarters since.
Moore Capital Management's Ultragenyx Pharmaceutical position peaked at $13.6M in Q3 2024.
311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Moore Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.